GLP1R and type 2 diabetes mellitus: Conversely, the magnitude of effect size seen following tirzepatide treatment is large, reducing the risk of incident T2D by 27%, which is conservative given our control group consisted of patients prescribed semaglutide; a potent GLP-1 RA.20